Previous Close | 46.51 |
Open | 46.51 |
Bid | 0.00 x 0 |
Ask | 0.00 x 0 |
Day's Range | 46.51 - 46.51 |
52 Week Range | 40.29 - 46.51 |
Volume | |
Avg. Volume | 3 |
Market Cap | 6.337B |
Beta (5Y Monthly) | 0.48 |
PE Ratio (TTM) | 17.69 |
EPS (TTM) | 2.63 |
Earnings Date | N/A |
Forward Dividend & Yield | 1.71 (3.69%) |
Ex-Dividend Date | Mar 23, 2023 |
1y Target Est | N/A |
ORION CORPORATION PRESS RELEASE 23 March 2023 at 15:00 EET Orion and Bayer expand clinical development program for darolutamide in prostate cancer Phase III study ARASTEP initiated in hormone-sensitive prostate cancer, in patients with high-risk biochemical recurrence (BCR) who have no evidence of metastatic disease by conventional imaging and a positive PSMA PET/CT at baselineFifth major clinical trial for androgen receptor inhibitor (ARi) darolutamide, covering prostate cancer from early to me
ORION CORPORATION STOCK EXCHANGE RELEASE / OTHER INFORMATION DISCLOSED ACCORDING TO THE RULES OF THE EXCHANGE22 MARCH 2023 at 17.15 EET Orion Corporation: Organising meeting of the Board of Directors In its organising meeting, the Board of Directors of Orion Corporation, which was elected today by the Annual General Meeting of the Shareholders, has elected Hilpi Rautelin as Vice Chair. The compositions of the Board committees were decided to be as follows: Personnel and Remuneration Committee:Mi
ORION CORPORATION STOCK EXCHANGE RELEASE / DECISIONS OF GENERAL MEETING22 MARCH 2023 at 16.30 EET Decisions taken by Orion Corporation’s Annual General Meeting on 22 March 2023 At the Annual General Meeting of Orion Corporation held today, the following decisions were made: A dividend of EUR 1.60 per share was confirmed to be paid. The record date for the dividend payment is 24 March 2023 and the payment date is 31 March 2023.The proposals concerning the election and remuneration of the Board of